Skip to main content
Top
Published in: Molecular Cancer 1/2023

Open Access 01-12-2023 | Prostate Cancer | Correspondence

Spatial transcriptomic analysis of virtual prostate biopsy reveals confounding effect of tissue heterogeneity on genomic signatures

Authors: Sandy Figiel, Wencheng Yin, Dimitrios Doultsinos, Andrew Erickson, Ninu Poulose, Reema Singh, Anette Magnussen, Thineskrishna Anbarasan, Renuka Teague, Mengxiao He, Joakim Lundeberg, Massimo Loda, Clare Verrill, Richard Colling, Pelvender S. Gill, Richard J. Bryant, Freddie C. Hamdy, Dan J. Woodcock, Ian G. Mills, Olivier Cussenot, Alastair D. Lamb

Published in: Molecular Cancer | Issue 1/2023

Login to get access

Abstract

Genetic signatures have added a molecular dimension to prognostics and therapeutic decision-making. However, tumour heterogeneity in prostate cancer and current sampling methods could confound accurate assessment. Based on previously published spatial transcriptomic data from multifocal prostate cancer, we created virtual biopsy models that mimic conventional biopsy placement and core size. We then analysed the gene expression of different prognostic signatures (OncotypeDx®, Decipher®, Prostadiag®) using a step-wise approach with increasing resolution from pseudo-bulk analysis of the whole biopsy, to differentiation by tissue subtype (benign, stroma, tumour), followed by distinct tumour grade and finally clonal resolution. The gene expression profile of virtual tumour biopsies revealed clear differences between grade groups and tumour clones, compared to a benign control, which were not reflected in bulk analyses. This suggests that bulk analyses of whole biopsies or tumour-only areas, as used in clinical practice, may provide an inaccurate assessment of gene profiles. The type of tissue, the grade of the tumour and the clonal composition all influence the gene expression in a biopsy. Clinical decision making based on biopsy genomics should be made with caution while we await more precise targeting and cost-effective spatial analyses.
Appendix
Available only for authorised users
Literature
1.
go back to reference Erickson A, Hayes A, Rajakumar T, Verrill C, Bryant RJ, Hamdy FC, et al. A systematic review of prostate Cancer heterogeneity: understanding the Clonal Ancestry of Multifocal Disease. Eur Urol Oncol. 2021;4(3):358–69.CrossRefPubMed Erickson A, Hayes A, Rajakumar T, Verrill C, Bryant RJ, Hamdy FC, et al. A systematic review of prostate Cancer heterogeneity: understanding the Clonal Ancestry of Multifocal Disease. Eur Urol Oncol. 2021;4(3):358–69.CrossRefPubMed
2.
go back to reference Cucchiara V, Cooperberg MR, Dall’Era M, Lin DW, Montorsi F, Schalken JA, et al. Genomic markers in prostate Cancer decision making. Eur Urol. 2018;73(4):572–82.CrossRefPubMed Cucchiara V, Cooperberg MR, Dall’Era M, Lin DW, Montorsi F, Schalken JA, et al. Genomic markers in prostate Cancer decision making. Eur Urol. 2018;73(4):572–82.CrossRefPubMed
3.
go back to reference Boström PJ, Bjartell AS, Catto JWF, Eggener SE, Lilja H, Loeb S, et al. Genomic predictors of outcome in prostate Cancer. Eur Urol. 2015;68(6):1033–44.CrossRefPubMed Boström PJ, Bjartell AS, Catto JWF, Eggener SE, Lilja H, Loeb S, et al. Genomic predictors of outcome in prostate Cancer. Eur Urol. 2015;68(6):1033–44.CrossRefPubMed
4.
go back to reference Lamy PJ, Allory Y, Gauchez AS, Asselain B, Beuzeboc P, de Cremoux P, et al. Prognostic biomarkers used for localised prostate Cancer Management: a systematic review. Eur Urol Focus. 2018;4(6):790–803.CrossRefPubMed Lamy PJ, Allory Y, Gauchez AS, Asselain B, Beuzeboc P, de Cremoux P, et al. Prognostic biomarkers used for localised prostate Cancer Management: a systematic review. Eur Urol Focus. 2018;4(6):790–803.CrossRefPubMed
5.
go back to reference Kretschmer A, Tilki D. Biomarkers in prostate cancer - current clinical utility and future perspectives. Crit Rev Oncol Hematol. 2017;120:180–93.CrossRefPubMed Kretschmer A, Tilki D. Biomarkers in prostate cancer - current clinical utility and future perspectives. Crit Rev Oncol Hematol. 2017;120:180–93.CrossRefPubMed
6.
go back to reference Erickson A, He M, Berglund E, Marklund M, Mirzazadeh R, Schultz N, et al. Spatially resolved clonal copy number alterations in benign and malignant tissue. Nature. 2022;608(7922):360–7.CrossRefPubMedPubMedCentral Erickson A, He M, Berglund E, Marklund M, Mirzazadeh R, Schultz N, et al. Spatially resolved clonal copy number alterations in benign and malignant tissue. Nature. 2022;608(7922):360–7.CrossRefPubMedPubMedCentral
7.
go back to reference Klein EA, Cooperberg MR, Magi-Galluzzi C, Simko JP, Falzarano SM, Maddala T, et al. A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling. Eur Urol. 2014;66(3):550–60.CrossRefPubMed Klein EA, Cooperberg MR, Magi-Galluzzi C, Simko JP, Falzarano SM, Maddala T, et al. A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling. Eur Urol. 2014;66(3):550–60.CrossRefPubMed
8.
go back to reference Erho N, Crisan A, Vergara IA, Mitra AP, Ghadessi M, Buerki C, et al. Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy. PLoS ONE. 2013;8(6):e66855.CrossRefPubMedPubMedCentral Erho N, Crisan A, Vergara IA, Mitra AP, Ghadessi M, Buerki C, et al. Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy. PLoS ONE. 2013;8(6):e66855.CrossRefPubMedPubMedCentral
9.
go back to reference Kamoun A, Cancel-Tassin G, Fromont G, Elarouci N, Armenoult L, Ayadi M, et al. Comprehensive molecular classification of localized prostate adenocarcinoma reveals a tumour subtype predictive of non-aggressive disease. Ann Oncol. 2018;29(8):1814–21.CrossRefPubMed Kamoun A, Cancel-Tassin G, Fromont G, Elarouci N, Armenoult L, Ayadi M, et al. Comprehensive molecular classification of localized prostate adenocarcinoma reveals a tumour subtype predictive of non-aggressive disease. Ann Oncol. 2018;29(8):1814–21.CrossRefPubMed
10.
go back to reference Falzarano SM, Ferro M, Bollito E, Klein EA, Carrieri G, Magi-Galluzzi C. Novel biomarkers and genomic tests in prostate cancer: a critical analysis. Minerva Urol Nefrol. 2015;67(3):211–31.PubMed Falzarano SM, Ferro M, Bollito E, Klein EA, Carrieri G, Magi-Galluzzi C. Novel biomarkers and genomic tests in prostate cancer: a critical analysis. Minerva Urol Nefrol. 2015;67(3):211–31.PubMed
11.
go back to reference Wei L, Wang J, Lampert E, Schlanger S, DePriest AD, Hu Q, et al. Intratumoral and Intertumoral genomic heterogeneity of multifocal localized prostate Cancer Impacts Molecular Classifications and genomic prognosticators. Eur Urol. 2017;71(2):183–92.CrossRefPubMed Wei L, Wang J, Lampert E, Schlanger S, DePriest AD, Hu Q, et al. Intratumoral and Intertumoral genomic heterogeneity of multifocal localized prostate Cancer Impacts Molecular Classifications and genomic prognosticators. Eur Urol. 2017;71(2):183–92.CrossRefPubMed
12.
go back to reference Cooperberg MR, Erho N, Chan JM, Feng FY, Fishbane N, Zhao SG, et al. The diverse genomic Landscape of clinically low-risk prostate Cancer. Eur Urol. 2018;74(4):444–52.CrossRefPubMedPubMedCentral Cooperberg MR, Erho N, Chan JM, Feng FY, Fishbane N, Zhao SG, et al. The diverse genomic Landscape of clinically low-risk prostate Cancer. Eur Urol. 2018;74(4):444–52.CrossRefPubMedPubMedCentral
Metadata
Title
Spatial transcriptomic analysis of virtual prostate biopsy reveals confounding effect of tissue heterogeneity on genomic signatures
Authors
Sandy Figiel
Wencheng Yin
Dimitrios Doultsinos
Andrew Erickson
Ninu Poulose
Reema Singh
Anette Magnussen
Thineskrishna Anbarasan
Renuka Teague
Mengxiao He
Joakim Lundeberg
Massimo Loda
Clare Verrill
Richard Colling
Pelvender S. Gill
Richard J. Bryant
Freddie C. Hamdy
Dan J. Woodcock
Ian G. Mills
Olivier Cussenot
Alastair D. Lamb
Publication date
01-12-2023
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2023
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/s12943-023-01863-2

Other articles of this Issue 1/2023

Molecular Cancer 1/2023 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine